Key facts
- Novelty Nobility’s last known valuation is $10.8M.
- It has raised $60.8M; the latest was Merger/Acquisition ($10.8M) in Aug 2025.
- Notable investors include KB Investment, Mirae Asset Capital, Shinhan Venture Investment, Johnson & Johnson Innovation - JLABS, KDB Capital — 29 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 29 names
- ·Watchlist + deal alerts for Novelty Nobility
- ·The full record, as it builds
Funding rounds
No funding rounds for Novelty Nobility are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Novelty Nobility
Operator of a biotech company intended to develop antibodies and antibody-drug conjugates to overcome drug resistance. The company focuses on researching novel factors for angiogenesis to develop therapeutic antibodies for treating diseases caused by the growth of aberrant blood vessels, such as retinal diseases and solid cancerous tumors, enabling clients to access new therapeutic options in ophthalmology and oncology for their patients.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2017
- Employees
- 35
- Website
- noveltynobility.com/
- Ownership
- Privately Held (backing)
Novelty Nobility doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Novelty Nobility shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Novelty Nobility in its N-PORT filings yet. We sweep new filings monthly.